Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kingsoft Cloud Holdings Limited (KC) vs Merck & Co., Inc. (MRK) Price & Performance

Kingsoft Cloud Holdings LimitedTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Kingsoft Cloud Holdings Limited vs Merck & Co., Inc. — how do they compare? Kingsoft Cloud Holdings Limited trades at $10.14 (market cap $3.01B), while Merck & Co., Inc. trades at $125.56 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 102.1× Kingsoft Cloud Holdings Limited's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals.

KCMRK
Market Cap
$3.01B$307.25B
Sector
TechnologyHealth
52-Week High
$18.21$129.52
52-Week Low
$8.58$77.60
Enterprise Value
$3.32B$350.66B
Dividend Yield
2.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kingsoft Cloud Holdings Limited

Kingsoft Cloud (KC) trades at $10.04, up 5.24% today, showing strong momentum despite a bearish technical signal. The company reported Q1 2026 revenue growth of 37% year-over-year, driven by AI cloud demand, though profitability remains challenged with a -9.39% net margin. Analyst sentiment is positive with 70% buy ratings, citing potential from AI expansion and trade easing between the U.S. and China.

KC presents a growth opportunity in cloud and AI services with strong revenue acceleration, but investors face risks from persistent losses, high capital expenditure, and competitive pressures. The stock's outlook hinges on margin improvement from AI investments and sustained demand, making it suitable for growth-oriented investors tolerant of near-term volatility.

Merck & Co., Inc.

Merck (MRK) trades at $125.25, down 1.76% on the day, with a neutral technical signal. The company reported strong earnings beats in recent quarters, with Q1 2026 results surpassing expectations. Fundamentals show robust profitability with a 73.91% gross margin and 13.59% net margin, though valuations are elevated with a P/E of 35.04. Recent news highlights the company's strategic acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.

The outlook is supported by a strong analyst consensus with a $137.30 price target and 68% buy ratings, but risks include high valuation multiples, competitive pressures in oncology, and significant capital expenditure for pipeline development as indicated by negative investing cash flow trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kingsoft Cloud Holdings Limited

Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.

Read more on KC

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK